<< Back To Authors

Overview

Liz Highleyman

Liz is Science Editor for Cancer Health, POZ, Hep and Real Health. She has been a health journalist and medical editor for more than 20 years, covering HIV, viral hepatitis, cancer and other health issues.

Articles

DHHS Updates Hepatitis B Guidelines for People With HIV

Revised recommendation address vaccination for HIV-positive people and treatment for those with HIV/HBV coinfection.

Can Doubling Dolutegravir Shrink the Viral Reservoir?

Unlike prior studies, new research finds antiretroviral intensification appears to reduce latent HIV in peripheral blood cells.

Twice-Yearly HIV PrEP Is the Breakthrough of the Year. Could It Be Annual?

Gilead is working on new formulations of injectable lenacapavir that could be administered just once a year.

IAS-USA Updates HIV Treatment and Prevention Recommendations

Revised recommendations include long-acting treatment and PrEP, prevention of STIs and cardiovascular risk management.

Twice-Yearly Lenacapavir PrEP Highly Effective in Second Study [UPDATED]

Results for gay men and gender-diverse people confirm stellar HIV prevention findings for women reported this summer.

Loneliness Linked to Frailty in Older People With HIV

Findings underscore the importance of recognizing and addressing social isolation among people aging with HIV.

Heart Fat Linked to Liver Fibrosis in People With HIV

People with increased epicardial fat thickness have a higher likelihood of fibrosis even if they have normal liver function tests.

Schematic image of the human immunodeficiency virus

Metformin May Help Shrink HIV Viral Reservoir

The diabetes drug could potentially be used as part of a “shock and kill” strategy to achieve a functional cure.

Hot topics

Forums: Support and discussion

Blogs: The community speaks

POZ Stories: Get inspired

Magazine: Search the archives

HIV: The Basics

Recursos de VIH/SIDA en Español

AIDS Is Everyday

Ask POZ

First Clade I Mpox Case Reported in United States

The likelihood of a U.S. outbreak is deemed to be low, but health officials are urging people at higher risk to get vaccinated.

Two-Drug Regimen Works Well for People With Advanced HIV

Additional data show Dovato (dolutegravir/lamivudine) is also a feasible option when drug-resistance testing is unavailable.

Prevention: HIV Risk for Women

The team identified 14 species of vaginal bacteria linked to HIV acquisition.

DHHS Updates HIV Guidelines

The guidelines also feature updated recommendations for older people living with HIV, transgender people and more.

Cure: CRISPR Gene Therapy

Findings suggest CRISPR-based therapies might play a role in a combination functional cure strategy

Pain Management Program for People With HIV

A majority of people with HIV experience persistent pain, which can lead to disability and difficulty adhering to antiretroviral treatment.

Treatment: Drug Resistance

Findings suggest that switching to Dolutegravir/lamivudine could be a cost-saving approach, especially in lower-income countries.

People Living With HIV Have Unmet Needs

Physical and mental health, subsistence needs and stigma can all affect quality of life for people living with HIV.